Bladder Cancer and Bladder-Sparing Therapy
Clinical research includes molecularly categorized muscle invasive bladder cancer, with interest in preserving the bladder while treating locally advanced disease.
- Muscle invasive bladder cancer
- Bladder-intact survival
- Immune-based treatment
The sponsor’s work in this area reflects a focus on treatment strategies that balance cancer control with organ preservation.
Neuroendocrine Targeted Oncology
Another area of interest is recurrent or relapsed solid tumours expressing somatostatin receptors, with attention to receptor-directed cancer care.
- Somatostatin receptor expression
- Recurrent or relapsed solid tumours
- Targeted radionuclide therapy
This research domain centers on tumors selected by molecular markers that can guide targeted therapeutic approaches.
Pediatric and Adolescent Oncology
Trials also extend to children and adolescents with relapsed solid tumours, showing interest in age-specific cancer treatment.
- Pediatric solid tumours
- Adolescent oncology
- Relapsed disease
The clinical focus includes cancers that require tailored therapeutic options for younger patients with limited treatment choices.
Combination Cancer Therapy
The sponsor is involved in studies of combined radioligand therapy and PARP inhibition, with attention to safety, tolerability, and antitumor activity.
- Radioligand therapy
- PARP inhibitors
- Treatment tolerability
These studies reflect an interest in pairing molecularly directed treatments to address resistant or recurrent cancers.
Quality of Life in Oncology Care
Across its studies, the sponsor includes quality of life as a key clinical area, alongside disease control and treatment feasibility.
- Patient-reported outcomes
- Treatment burden
- Supportive oncology
This indicates sustained attention to how cancer therapies affect daily functioning and overall patient experience.
